Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) Toolkit
Following closing, the company will have an expanded pipeline that contains multiple compelling assets spanning early and late development stages.
- Following closing, the company will have an expanded pipeline that contains multiple compelling assets spanning early and late development stages.
- An assessment of the pipeline is planned, including program prioritization, updated timelines, near-term value creation opportunities, and other considerations.
- Key highlights of the merger include:
The merged pipeline features a robust ADC toolkit with novel payload and linker technologies. - Goodwin Procter LLP is serving as legal advisor to Akari and DLA Piper LLP is serving as legal advisor to Peak Bio.